Feasibility and Efficacy of Local Radiotherapy With Concurrent Novel Agents in Patients With Multiple Myeloma.
CONCLUSION: Treating MM with RT concurrently with CTx including NAs was safe and well tolerated in the majority of patients (14 of 16 [87.5%] for those taking NAs and 19 of 21 [90.5%] for all patients). Excellent clinical pain response (> 95%) was also seen in patients regardless if they were treated with RT + ST or RT alone. PMID: 25176474 [PubMed - as supplied by publisher]
Conclusions: LCDD can affect the lungs in the form of cysts and nodules, especially in the setting of Sjögren’s syndrome.
CONCLUSIONS: Palliative care was provided to a minority of patients with hematologic malignancies and considerable improvement is required in its timely use and extension. PMID: 31714147 [PubMed - as supplied by publisher]
CONCLUSION: All tested biosimilars demonstrated similar effectiveness and safety profiles in patients with hematological tumors undergoing PBSC mobilization; therefore, they can be used interchangeably. PMID: 31663634 [PubMed - as supplied by publisher]
An ongoing phase 3 trial of transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) demonstrated significant improvement in progression-free survival with daratumumab, lenalidomide, and dexamethasone (D-Rd) vs Rd alone (MAIA clinical trial; Facon T, et al. N Engl J Med. 2019;380:2104-15). Bone pain is a common presenting symptom in patients with multiple myeloma (MM), and pain has a significant impact on a person's everyday activity and health-related quality of life (HRQoL).
Multiple myeloma (MM) is characterized by excessive proliferation and accumulation of abnormal plasma cells infiltrating the bone marrow microenvironment. It is characterized by secretion of atypical monoclonal immunoglobulin (M protein) by plasma cells in blood or urine, anemia, hypercalcemia, renal dysfunction, and bone pain accompanied with pathological fractures. Approximately 70% of MM patients display skeletal abnormalities at diagnosis and after diagnosis nearly 85% patients develop bone lesions during the course o f disease.
In October 2015, a 58-year-old male was presented to Hematology, Oncology and Stem Cell Transplantation Research Center; Tehran University of Medical Sciences, Tehran, Iran, with complaints of bone pain and decreased urine volume about 2 months prior to admission. Initial laboratory findings demonstrated a normocytic, normochromic anemia with a hemoglobin of 8.2 g/dL, a white blood cell count (WBC) of 6,500 cell/mm3, and a platelets count of 245,000/mm. He had a creatinine of 4.2 mg/dL, calcium of 12.5 mg/dL, albumin of 3.7 g/dL, total protein of 11.7 g/dL, Beta-2 microglobulin of 13.8mg/L, and an erythrocyte sedimentation...
We describe a case of Stage 3 PBMM diagnosed in a 53-year-old AA male diagnosed during evaluation of chest pain. In addition, multiple rare and distinguishing high-risk cytogenetic features were noted on FISH analysis.
Myeloma bone disease (MBD) is an important unmet medical need characterized by focal and generalized bone loss causing severe pain, pathological fractures, instability of the vertebral column, and medullary cord / spinal nerve root compression. MBD is a disease-defining feature of multiple myeloma, the second most common blood cancer in the United States. MBD is poorly recapitulated in genetically engineered mouse models (GEMMs) of human myeloma developed in the past. Objective: To address this shortcoming, we determined onset, incidence and severity of osteolytic disease in a new GEMM of human myeloma developed in our laboratory.
CONCLUSION: CART-related GI-AEs occur in 15% of patients treated with CART. These symptoms are typically mild and self-limiting, requiring only symptomatic treatment. Nevertheless, CART may, in rare cases, lead to refractory colitis. PMID: 31478934 [PubMed - as supplied by publisher]
ConclusionWe recommend routine screening for venous thrombosis in any case of MPN when diagnosed and screening for MPNs in any patient with venous thrombosis especially of the portal vein or atypical sites. If MPN patients present with increasing pruritus or abdominal pain, they also should be screened for venous thrombosis. Further research on a large scale in MPN age groups younger than 60 years regarding pathogenesis of thrombosis is highly recommended.